Abstract
The purine nucleoside analog - cladribine (2-chlorodeoxyadenosine, 2-CdA) is a cytotoxic agent with high activity in lymphoid and myeloid malignancies. It is also an effective drug in some autoimmune disorders. 2-CdA is usually administered intravenously in continuous or 2-hour infusion. Recently however, new formulation of this agent has been developed for subcutaneous and oral administration. 2-CdA is widely established as first line standard treatment for hairy cell leukemia. Moreover several clinical trials have demonstrated that this agent, used alone or in combination with other cytotoxic drugs, showed good efficacy and acceptable toxicity profile in the treatment of chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, low-grade non-Hodgkins lymphoma and acute myeloid leukemia. Moreover, some studies indicate that 2-CdA has some activity in progressive multiple sclerosis and other autoimmune disorders including autoimmune hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus, psoriasis and in patients with refractory factor VIII inhibitors. This review article will summarize the results of recent clinical trials with 2- CdA in hematological malignancies, multiple sclerosis and other autoimmune diseases.
Keywords: Cladribine, clinical trials, leukemia, lymphoma, multiple sclerosis, autoimmune disease
Reviews on Recent Clinical Trials
Title: Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Volume: 1 Issue: 1
Author(s): Tadeusz Robak, Agnieszka Wierzbowska and Ewa Robak
Affiliation:
Keywords: Cladribine, clinical trials, leukemia, lymphoma, multiple sclerosis, autoimmune disease
Abstract: The purine nucleoside analog - cladribine (2-chlorodeoxyadenosine, 2-CdA) is a cytotoxic agent with high activity in lymphoid and myeloid malignancies. It is also an effective drug in some autoimmune disorders. 2-CdA is usually administered intravenously in continuous or 2-hour infusion. Recently however, new formulation of this agent has been developed for subcutaneous and oral administration. 2-CdA is widely established as first line standard treatment for hairy cell leukemia. Moreover several clinical trials have demonstrated that this agent, used alone or in combination with other cytotoxic drugs, showed good efficacy and acceptable toxicity profile in the treatment of chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, low-grade non-Hodgkins lymphoma and acute myeloid leukemia. Moreover, some studies indicate that 2-CdA has some activity in progressive multiple sclerosis and other autoimmune disorders including autoimmune hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus, psoriasis and in patients with refractory factor VIII inhibitors. This review article will summarize the results of recent clinical trials with 2- CdA in hematological malignancies, multiple sclerosis and other autoimmune diseases.
Export Options
About this article
Cite this article as:
Robak Tadeusz, Wierzbowska Agnieszka and Robak Ewa, Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders, Reviews on Recent Clinical Trials 2006; 1 (1) . https://dx.doi.org/10.2174/157488706775246102
DOI https://dx.doi.org/10.2174/157488706775246102 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer
Recent Patents on Anti-Cancer Drug Discovery Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism Brain Tumor-Related Epilepsy
Current Neuropharmacology Editorial (Thematic Issue: Thyroid Hormones. From Molecular Signaling to Human Disease: An Update)
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Anandamide Degradation System as Potential Target for the Treatment of Central Nervous System Related Disorders
Current Medicinal Chemistry - Central Nervous System Agents Bladder Cancer: A Simple Model Becomes Complex
Current Genomics Rheb/mTOR Activation and Regulation in Cancer: Novel Treatment Strategies beyond Rapamycin
Current Drug Targets In Vitro and In Vivo Experimental Model-based Approaches for Investigating Anti-inflammatory Properties of Coumarins
Current Medicinal Chemistry Haploinsufficiency of DNA Damage Response Genes and their Potential Influence in Human Genomic Disorders
Current Genomics Clinical Benefit of Idiotype Vaccines: Too Many Trials for a Clever Demonstration?
Reviews on Recent Clinical Trials Editorial [Hot Topic: The Fabisch-Symposium 2009 on Targeted Tumor Therapies(Guest Editors: C. Bachran and H. Fuchs)]
Current Drug Targets Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Photosensitization of Biomolecules by Phenothiazine Derivatives
Current Drug Targets Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery
Current Medicinal Chemistry From Bone Marrow Transplantation to Cellular Therapies: Possible Therapeutic Strategies in Managing Autoimmune Disorders
Current Pharmaceutical Design Clinical Update: Treatment of Glioblastoma Multiforme with Radiolabeled Antibodies that Target Tumor Necrosis
Current Cancer Therapy Reviews Sodium Selenite as an Anticancer Agent
Anti-Cancer Agents in Medicinal Chemistry Human Whey Promotes Sessile Bacterial Growth, Whereas Alternative Sources of Infant Nutrition Promote Planktonic Growth
Current Nutrition & Food Science